LRI Investments LLC Boosts Stake in Gilead Sciences, Inc. $GILD

LRI Investments LLC raised its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 10.3% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,478 shares of the biopharmaceutical company’s stock after buying an additional 138 shares during the quarter. LRI Investments LLC’s holdings in Gilead Sciences were worth $164,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in GILD. Price T Rowe Associates Inc. MD boosted its holdings in shares of Gilead Sciences by 314.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company’s stock worth $1,647,484,000 after purchasing an additional 11,156,382 shares in the last quarter. Nuveen LLC bought a new stake in Gilead Sciences in the 1st quarter worth approximately $620,415,000. Kingstone Capital Partners Texas LLC bought a new stake in Gilead Sciences in the 2nd quarter worth approximately $238,083,000. Los Angeles Capital Management LLC lifted its position in Gilead Sciences by 422.6% in the 1st quarter. Los Angeles Capital Management LLC now owns 2,523,036 shares of the biopharmaceutical company’s stock worth $282,706,000 after buying an additional 2,040,261 shares during the last quarter. Finally, Vanguard Group Inc. lifted its position in Gilead Sciences by 1.7% in the 1st quarter. Vanguard Group Inc. now owns 117,470,825 shares of the biopharmaceutical company’s stock worth $13,162,606,000 after buying an additional 1,942,433 shares during the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction that occurred on Monday, September 15th. The stock was sold at an average price of $113.57, for a total value of $283,925.00. Following the completion of the transaction, the chief financial officer owned 159,555 shares of the company’s stock, valued at approximately $18,120,661.35. This represents a 1.54% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Johanna Mercier sold 28,000 shares of the stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $118.53, for a total value of $3,318,840.00. Following the completion of the transaction, the insider directly owned 114,168 shares of the company’s stock, valued at $13,532,333.04. This represents a 19.70% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 77,000 shares of company stock valued at $8,853,430. Corporate insiders own 0.27% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently weighed in on the company. Citigroup boosted their target price on Gilead Sciences from $125.00 to $135.00 and gave the stock a “buy” rating in a research report on Wednesday, October 8th. Daiwa Capital Markets upgraded Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 target price for the company in a research report on Tuesday, August 19th. Dbs Bank upgraded Gilead Sciences to a “moderate buy” rating in a research report on Friday, September 5th. Truist Financial upgraded Gilead Sciences from a “hold” rating to a “buy” rating and boosted their target price for the stock from $108.00 to $127.00 in a research report on Friday, August 8th. Finally, Cantor Fitzgerald increased their target price on Gilead Sciences from $129.00 to $135.00 and gave the company an “overweight” rating in a report on Thursday. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $118.08.

Gilead Sciences Trading Up 0.4%

NASDAQ GILD opened at $117.18 on Monday. Gilead Sciences, Inc. has a fifty-two week low of $84.17 and a fifty-two week high of $121.83. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. The stock has a 50 day simple moving average of $114.65 and a two-hundred day simple moving average of $110.25. The stock has a market cap of $145.40 billion, a P/E ratio of 23.34, a price-to-earnings-growth ratio of 0.80 and a beta of 0.34.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, topping the consensus estimate of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The business had revenue of $7.08 billion during the quarter, compared to analysts’ expectations of $6.95 billion. During the same quarter last year, the business posted $2.01 EPS. The business’s revenue was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, September 29th. Stockholders of record on Monday, September 15th were given a $0.79 dividend. The ex-dividend date of this dividend was Monday, September 15th. This represents a $3.16 annualized dividend and a dividend yield of 2.7%. Gilead Sciences’s dividend payout ratio is currently 62.95%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.